Adicet Bio, Inc. (LON: 0HX7)

Market Cap	61.42M
Revenue (ttm)	n/a
Net Income (ttm)	-87.95M
Shares Out	n/a
EPS (ttm)	-1.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97
Average Volume	3,956
Open	0.907
Previous Close	0.898
Day's Range	0.907 - 0.915
52-Week Range	0.907 - 7.600
Beta	n/a
RSI	44.79
Earnings Date	Mar 20, 2025

About Adicet Bio

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Th...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2014
• Employees: 143
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HX7

Financial Performance

Financial numbers in USD